|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Zogenix, Inc. Drug May be Abused at Higher Rate, FDA Staff Says
12/5/2012 7:52:45 AM
Zogenix Inc. (ZGNX)’s pure hydrocodone painkiller Zohydro may be abused at a greater rate if approved than combination products on the market, U.S. regulators said. Food and Drug Administration staff asked outside advisers in a report today to weigh the effectiveness of the extended- release pill against its risk of abuse. The advisers will meet Dec. 7 to decide whether to recommend the medicine’s approval. Zogenix, whose $38 million in revenue last year came from migraine injection Sumavel, may get more than $200 million in sales from Zohydro, Annabel Samimy, a Stifel Nicolaus & Co. analyst in New York, said in a note to clients last month. Zogenix, based in San Diego, touts Zohydro as the only pure alternative to hydrocodone-combination painkillers, such as the acetaminophen-mixed Vicodin, which carry a risk of liver injury. “It is expected that Zohydro ER (if approved and marketed) will be associated with higher levels of abuse than the hydrocodone combination products,” the FDA staff said in the report. Zogenix fell 4.7 percent to $2.41 at 9:17 a.m. New York time.
|
|
|
|
|
|
|
|
|
|
|